n CME : Your SA Journal of CPD - Management of multiple myeloma : main article

Volume 25, Issue 6
  • ISSN : 0256-2170



  • Multiple myeloma has a chronic progressive course if not adequately treated.
  • Standard treatment with melphalan and prednisone is inferior to current therapies.
  • Thalidomide combined with dexamethasone is the treatment of choice for induction therapy.
  • High-dose melphalan with stem cell rescue induces high complete remission rates and prolongs overall survival.
  • Maintenance thalidomide should be given post stem cell transplant.
  • Proteosome inhibitors are currently reserved for the relapsed refractory patients.
  • Patients who do not qualify for stem cell transplant should receive melphalan and prednisone combined with thalidomide.
  • Complete remission should be the goal of therapy.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error